Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
UBS
Deloitte
Healthtrust
Colorcon
Express Scripts
Citi
Cipla
Queensland Health
Johnson and Johnson

Generated: August 16, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Method of treating multiple sclerosis
Abstract:A method of treating neuroimmunologic diseases such as multiple sclerosis and acute disseminated encephalomyelitis using 1,4-dihydroxy-5,8-bis[[(2-hydroxyethylamino)ethyl]amino]anthraquinone, or a pharmacologically acceptable acid addition salt thereof.
Inventor(s): Kerwar; Suresh S. (Ossining, NY), Sloboda; Adolph E. (New City, NY), Ridge; Susan C. (Valley Cottage, NY)
Assignee: American Cyanamid Company (Stamford, CT)
Application Number:06/744,370
Patent Claims: 1. A method of treating neuroimmunologic diseases in a mammal which comprises administering parenterally to said mammal from about 0.25 to about 0.5 mg per kilogram of body weight per day of a compound selected from 1,4-dihydroxy-5,8-bis[[2-(2-hydroxethylamino)ethyl]amino]-anthraquinone and the pharmacologically acceptable acid addition salts thereof.

2. A method according to claim 1, wherein the compound is 4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl]amino]anthraquinone, dihydrochloride.

3. A method according to claim 1, wherein the compound is administered intraperitoneally.

4. A method according to claim 1, wherein the neuroimmunologic disease is multiple sclerosis.

5. A method according to claim 1, wherein the neuroimmunologic disease is acute disseminated encephalomyelitis.

6. A method of treating neuroimmunologic diseases in mammals which comprises administering parenterally an sufficient amount of 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl]amino]anthraquinone or a pharmacologically acceptable acid addition salt thereof to palliate muscular weakness and paralysis symptomatic of these diseases in said mammals.

7. A method according to claim 6, wherein the neuroimmunologic disease is multiple sclerosis.

8. A method according to claim 6, wherein the neuroimmunologic disease is acute disseminated encephalomyelitis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Chubb
Colorcon
Novartis
Fuji
AstraZeneca
Boehringer Ingelheim
Fish and Richardson
Covington
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot